β-cell regeneration to treat type 1 diabetes mellitus

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 1, 2008, Pages 51-60

  Eduardo, Carlos ^a   Couri, Barra ^a   Foss Freitas, Maria Cristina ^a   Foss, Milton César ^a   Voltarelli, Júlio César ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cell precursors; cell preservation; cell regeneration; Diabetes mellitus; Immune intervention; Stem cell

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; C PEPTIDE; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKERATIN 19; DACLIZUMAB; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN ZINC SUSPENSION; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OXYGEN; PLACEBO; PREDNISONE; RAPAMYCIN; RECOMBINANT HUMAN INSULIN; RITUXIMAB; THYMOCYTE ANTIBODY; VITAMIN D;

AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD GLUCOSE MONITORING; CELL DIFFERENTIATION; CELL REGENERATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETOGENESIS; DRUG MEGADOSE; EMBRYONIC STEM CELL; HUMAN; HYPERBARIC OXYGEN; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; KIDNEY PANCREAS TRANSPLANTATION; LEUKAPHERESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; STEM CELL MOBILIZATION; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 37549048001     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.1.51     Document Type: Review

References (89)

1. American Diabetes Association. Diagnosis and classification of diabetes. Diabetes Care 27(Suppl. I), S5-S10 (2004).
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab. Res. Rev. 15(3), 205-218 (1999).
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
5. Marshall AL, Chertwynd A, Morris JA et al. Type 1 diabetes mellitus in childhood: a matched case control study in Lancashire and Cumbria, UK. Diabet. Med. 21(9), 1035-1040 (2004).
6. Notkins AL, Lernmark A. Autoimmune Type 1 diabetes: resolved and unresolved issues. J. Clin. Invest. 108(9), 1247-1252 (2001).
7. Pozzilli P, Di Mario U. Autoimune diabetes not requiring insulin at diagnosis (latent autoimune diabetes of the adult). Diabetes Care 24(8), 1460-1467 (2001).
8. Palmer JP, Fleming GA, Greenbaum CJ et al. C-peptide is the appropriate outcome measure for Type 1 diabetes clinical trials to preserve β-cell function. Diabetes 53(1), 250-264 (2004).
9. Redondo MJ, Rewers M, Yu L et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with Type 1A diabetes: prospective twin study. BMJ 318(7319), 698-702 (1999).
10. Bennett ST, Todd JA. Human Type 1A diabetes and the insulin gene: principles of mapping polygenes. Annu. Rev. Genet. 30, 343-370 (1996).
11. Fairweather D L, Rose NR. Type 1 diabetes: virus infection or autoimmune disease? Nat. Immunol. 3(4), 383-340 (2002).
12. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 328(7442), 750-754 (2004).
13. Eizirik DL, Mandrup-Poulsen T. A choice of death: the signal transduction of immune-mediated β-cell apoptosis. Diabetologia 44, 2115-2133 (2001).
14. Eizirik DI, Kutlu B, Rasschaert J, Darville M, Cardozo AK. Use of microarray analysis to unveil transcription factor and gene networks contributing to β-cell dysfunction and apoptosis. Ann. NY Acad. Sci. 1005, 55-74, (2003).
15. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in Type 1 and Type 2 diabetes: many differences, few similarities. Diabetes 54(Suppl. 2), S97-S107 (2005).
16. The Epidemiology of Diabetes Interventions and Complications Research Group. The effect of intensive insulin therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA 287(19), 2563-2569 (2002).
17. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with Type 1 diabetes in the Diabetes Control and Complications Trial. Ann. Intern. Med. 128(7), 517-523 (1998).
18. Couri CE, Foss MC, Voltarelli JC. Secondary prevention of Type 1 diabetes mellitus: stopping immune destruction and promoting β-cell regeneration. Braz. J. Med. Biol Res. 39(10), 1271-1280 (2006).
19. Elliott RB, Berryman CC, Crossley JR, James AG. Partial preservation of pancreatic β-cell function in children with diabetes. Lancet, 19(2), 631-632 (1981).
20. Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increased in remission rate in newly diagnosed Type 1 diabetic subjects treated with azathioprine. Diabetes 34(12), 1306-1308 (1985).
21. Cook JJ, Hudson I, Harrison LC et al. Double-blind controlled trial of azathioprine in children with newly diagnosed Type I diabetes. Diabetes 38(6), 779-783(1989).
22. Silverstein J, Maclaren N, Riley W, Spillar R. Radjenovic D, Jonhson S. Immunosupression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319(10), 599-604 (1988).
23. Assan R, Feutren G, Sirmai J et al. Plasma C-peptide levels and clinical remissions in recent-onset Type 1 diabetic patients treated with cyclosporin A and insulin. Diabetes 39 (7), 768-774 (1990).
24. Bougnères F, Landais P, Boisson C et al. Limited duration of remission of insulin dependency in children with recent overt Type I diabetes treated with low-dose cyclosporin. Diabetes 39(10), 1264-1272 (1990).
25. Herold KC, Hagopian W. Auger JA et al. Anti-CD3 monoclonal antibodiy in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1692-1698 (2002).
26. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352(25), 2598-2608 (2005).
27. Raz I, Elias D, Avron A, Metzger M, Cohen IR. β-cell function in newly-onset Type 1 diabetes and immunomodulation with a heat shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet 358(9295), 1749-1753 (2001).
28. Saudek F, Havrdova T, Boucek P, Novota P, Skibova J. Polyclonal anti-T-cell therapy for Type 1 diabetes mellitus of recent onset. Rev. Diabet. Stud. 1(2), 80-88 (2004).
29. Burt RK. Slavin S, Burns WH, Marmont AM. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 99(3), 768-784 (2002).
30. Burt RK, Traynor A, Statkute L et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 295(5), 527-535 (2006).
31. Voltarelli JC, Couri CEB, Stracieri ABPL et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297(14), 1568-1576 (2007).
32. Voltarelli JC, Burt RK, Kenyon N, Kaufman DB, Squiers E. Hematopoictic stem cell transplantation as treatment for Type 1 diabetes. In: Stem Cell Therapy for Autoimmmune Diseases. Burt R, Marmont A (Eds). Landes Bioscience, TX, USA, 442-447 (2004).
33. European Nicotinamide Diabetes Intervention Trial Group: European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of Type 1 diabetes. Lancet 363(9413),925-931 (2004).
34. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N. Engl. J. Med. 346(22), 1685-1691(2002).
35. Diabetes Prevention Trial - Type 1 Study Group. Effects of oral insulin in relatives of patients with Type 1 diabetes. Diabetes Care 28(5), 1068-1076 (2005).
36. Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of Type 1 diabetes in NOD mice. Nature 435, 220-223 (2005).
37. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of Type 1 diabetes: a birth-cohort study. Lancet 358(9292), 1500-1503(2004).
38. Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on Type 1 diabetes: immune-based therapeutic approaches for Type 1 diabetes. Clin. Exp. Immunol. 148, 17-31 (2007).
39. Bonner-Weir S, Sharma A. Pancreatic stem cell. J. Pathol. 197(4), 519-526 (2002).
40. Swenne I. Pancreatic β-cell growth and diabetes mellitus. Diabetologia 35(3), 193-201 (1992).
41. Fernandes A, King LC, Guz Y, Stein R, Wright CV, Teitelman G. Differentiation of new insulin-producing cells is induced by injury in adult pancreatic islets. Endocrinology 138(4), 1750-1762 (1997).
42. Finegood DT, Scaglia R, Bonner-Weir S. Dynamics of β-cell mass in the growing rat pancreas: estimation with a simple mathematical model. Diabetes 44(3), 249-256 (1995).
43. Kuroda A, Yamasaki Y, Imagawa A. β-cell regeneration in a patient with Type 1 diabetes mellirus who was receiving immunosuppressive therapy. Ann. Intern. Med. 139(10), 81 (2003).
44. Fischbach GD, Fischbach RL. Stem cells: science, policy and ethics. J. Clin. Invest. 114(10), 1364-1370, (2004).
45. Wagers AJ, Weissman IL. Plasticity of adults stem cells. Cell 116(5), 639-648 (2004).
46. Seaberg R, Smulker SR, Kieffer TJ et al. Clonal identification of multipotent precursors from adult mouse pancreas that generate neural and pancreatic lineages. Nat. Biotechnol. 22(9), 1115-1124 (2004).
47. Georgia S, Blushan A. β cell replication is the primary mechanism of maintaining postnatal β cell mass. J Clin. Invest. 114 (7), 963-968 (2004).
48. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429(6987), 41-46 (2004).
49. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by β cell regeneration. J Clin. Invest. 117(9), 2553-2561 (2007).
50. Suzuki A, Nakauchi H, Tanigichi H. Prospective isolation of pancreatic multipotent progenitors using flow-cytometric cell sorting. Diabetes 53(8), 2143-2152 (2004).
51. Noguchi H. Stem cells for the treatment of diabetes. Endocr. J. 54(1), 7-16 (2007).
52. Bonner-Weir S, Taneja M, Weir GC et al. In vitro cultivation of human islets from expanded ductal tissue. Proc. Natl Acad. Sci. USA 97(14), 7999-8004 (2000).
53. Lechner A, Habener JF. Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 284(2), E259-E266 (2003).
54. Ianus A, Holz GG, Theise ND, Hussain MA. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest. 111(6), 843-850 (2003).
55. Choi JB, Uchino H, Azuma K et al. Little evidence of transdifferentiation of bone marrow-derived cells into pancreatic β cells. Diabetologia 46(10), 1366-1374 (2003).
56. Hess D, Li L, Martin M et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21, 763-770 (2003).
57. Mathews V, Hanson PT, Ford E, Fujita J, Polonsky KS, Graubert TA. Recruitment of bone marrow-derived endothelial cells to sites of pancreitic β-cell injury. Diabetes 53, 91-98 (2004).
58. Hasegawa Y, Ogiliara T, Yamada T et al. Bone marrow (BM) transplantation promotes β-cell regeneration after acute injury through BM cell mobilization. Endocrinology 148, 2006-2015 (2007).
59. Lagasse E, Connors H, Al-Dhalimy M et al. Purified hematopoietic stem cell can differentiate into hepatocytes in vivo. Nat. Med. 6(11), 1229-1234 (2000).
60. Theise ND, Badve S, Saxena R et al. Derivation of hepatocytes front bone marrow cells in mice after radiation-induced myeloablation. Hepatology, 31(1), 235-240 (2000).
61. Kang EM, Zickler MM, Burns S et al. Hematopoictic stem cell transplantation prevents diabetes in NOD mice but does not contribute to significant islet cell regeneration once disease is established. Exp. Hematol. 33(6), 699-705(2005).
62. Butler AE, Huang A, Rao PN et al. Hematopoietic stem cells derived from adult donors are not a source of pancreatic β-cells in adult nondiabetic humans. Diabetes 56(7), 1810-1816 (2007).
63. Nelson JL, Torres I, Louie FM et al. Preexisting autoimmune diseasein patients with long term survival after allogeneic bone marrow transplantation. J Rheumatol. 24(48), 23-29 (1997).
64. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult bone marrow. Nature 418(6893), 41-49 (2002).
65. Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet kells. World J. Gastroenterol. 10(20), 3016-3020 (2004).
66. Tang DQ Cao LZ, Burkhardt BR et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes 53(7), 1721-1732 (2004).
67. Lee HR, Seo MJ, Reger RL et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc. Natl Acad. Sci. USA 103(46), 17438-17443 (2006).
68. Sun Y, Chen L, Hou XG et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin. Med. J. (Engl.) 120 (9), 771-776 (2007).
69. Timper K, Seboek D, Eberhardt M et al. Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagons expressing cells. Biochem. Biophys. Res. Commun. 341(4), 1155-1160 (2006).
70. Ruhnke M, Ungefroren H, Nussler et al. Differentiation of in vitro-modified human peripheral blood monocyres into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 128(7), 1774-1786 (2005).
71. Tuma-Mubarak J, Fernandez-Viña R, Yalan AC et al. Autologous bone marrow mononuclear cell (ABMMC) transplantation in Type 1 and Type 2 insulin-dependent diabetes mellitus patients. International Society of Cell Therapy Meeting. Sydney, Australia 24-27 June (2007).
72. Novoa JE, Medina MA, Gordillo F et al. The Conzi's effect in human diabetes mellitus: from bone marrow progenitor cells (BMPCs) to β cells. Archivos de Medicina Interna 1(Suppl. 1), 34 (2007).
73. Ende N, Chen R, Reddi AS. Effect of human umbilical cord blood cells on glycemia and insulitis in Type 1 diabetic mice. Biochem. Biophys. Res. Commun. 325(3), 665-669 (2004).
74. Ende N, Chen R, Reddi AS. Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in Type 2 diabetic mice. Biochem. Biophys. Res. Commun. 321(1), 168-71 (2004).
75. Naruse K, Hamada Y, Nakashima E et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 54(6), 1823-1828 (2005).
76. Haller MJ, Viener HL, Brusko T et al. Insulin requirements, HbAlc, and stimulated C-peptide following autologous umbilical cord blood transfusion in children with T1D. Abstracts ADA 67th Scientific Sessions. A82 (2007).
77. Petersen BE, Goff JP, Greenberger JS, Michalopoulos GK. Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 27(2), 433-445 (1998).
78. Yang L, Li S, Hatch H et al. In vitro transdifferentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc. Natl Acad. Sci. USA 99(12), 8078-8083 (2002).
79. Kim S, Shin JS, Kim HJ, Fisher RC, Lee MJ, Kim CW. Streptozotocin-induced diabetes can be reversed by hepatic oval cell activation through hepatic transdifferentiation and pancreatic islet regeneration. Lab. Invest. 87(7), 702-712 (2007).
80. Assady S, Maor G, Amit M, Itskovitzs-Eldor J, Skorecki YL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes 50(8), 1691-1697 (2001).
81. Soria B, Roche E, Berna G, Leon-Quito T, Reig JA, Martin F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 49(2), 157-162 (2000).
82. Hansson M, Tonning A, Frandsen U et al. Artifactual insulin release from differentiated embryonic stem cells. Diabetes 53(10), 2603-2609 (2004).
83. Jaenisch R. Human cloning - the science and ethics of nuclear transplantation. N. Engl. J. Med. 351(27), 2787-2791 (2004).
84. Chong S, Normile D. Stem cells. How young Korean researchers helped unearth a scandal. Science 311(5757), 22-25 (2006).
85. Smykoduh OI, Noritskaya AV. Embryonic stem cells in new onset Type 2 diabetes mellitus. Cytotherapy 6(4), 402 (2004).
86. Smykodub OI, Noritskaya AV. Embryonic stem cells in pernicious decompensated Type 2 diabetes mellitus. Cytotherapy 6(4), 402 (2004).
87. Sinden JD. ReNeuron Group plc. Regenerative Med. 1(1), 143-147 (2006).
88. Colman A, Alliston D. ES Cell International and regenerative medicine. Regenerative Med. 1(2), 287-292 (2006).
89. Bresson D, von Herrath M. Moving towards efficient therapies in Type 1 diabetes: to combine or not to combine? Autoinumune Rev. 6(5), 315-322 (2007).